Milan, April 5, 2012– With reference to Sorin S.p.A. Ordinary and Extraordinary Shareholders’ Meeting, convened for April 27, 2012 (first call) and, if necessary, for April 30, 2012 (second call), Sorin informs that have been filed the following slates of candidates for the appointment of the new Board of Directors: 

• Slate no. 1, presented by Bios S.p.A., owner of 18.863% of Sorin S.p.A. ordinary shares: 

1. Ugo Smiraglia
2. Roberto Giay
3. Rosario Bifulco
4. André-Michel Ballester
5. Luigi Ragno (independent)
6. Giuseppe Carteni (independent)
7. Giovanni Pavese
8. Maurizia Squinzi
9. Andrea Bovone
10. Massimo Tononi
11. Paolo Baessato (independent)
12. Giorgio Mancuso
13. Daniela Toscani
14. Alessandro Dinardo
15. Pietro Santicoli

• Slate no. 2, jointly presented by the shareholders Zadig Gestion (Luxemburg) S.A. manager of the funds Zadig Master Fund and Memnon Fund - Memnon European Fund; Hermes Focus Asset Management Europe Ltd manager of the fund Hermes European Focus Fund and FIL Investments International manager of the funds: Fidelity Funds - Italy Pool, Fidelity Funds - Global Healthcare and Fidelity Funds - Euro Smaller Cies Pool 3, owners of a total of 4.094% of Sorin S.p.A. ordinary shares:

1. Gino Santini (independent)
2. Luciano Cattani (independent)
3. Laura Iris Ferro (independent)
4. Roberto Ferri (independent)
5. Ugo Ortelli (independent)

• Slate no. 3, jointly presented by the shareholders Selfid S.p.A., Banca Akros S.p.A., Almaf S.p.A., Enzo Ricci, Franco Vimercati and Maurizio Mauri, c owners of a total of 2.594% of Sorin S.p.A. ordinary shares: 

1. Maurizio Mauri (independent)
2. Sergio Dompè (independent)
3. Pietro Guindani (independent)
4. Giorgio Fossa (independent)
5. Marco Abramo Lanza (independent)

  
The documentation relative to the above slates is available at the Company’s registered office, at Borsa Italiana S.p.A. and on the Company’s website www.sorin.com(Investors section)
The following documents have also been published today at the above mentioned sites: i) the annual financial report, comprising the draft separate and consolidated financial statements at 31 December 2011, the directors' report and the certification required under art. 154-bis, clause 5, legislative decree 58/1998 (“TUF”), the reports of the board of statutory auditors and the statutory audit firm and the annual corporate governance and ownership report, along with other documents required under current law and regulations; ii) the remuneration report pursuant to art. 123-ter of TUF.
  
About Sorin Group
Sorin Group (www.sorin.com) is a global company and a leader in the treatment of cardiovascular diseases. The company develops, manufactures and markets medical technologies and innovative therapies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on three major therapeutic areas: cardiopulmonary bypass (extra-corporeal circulation and autotransfusion systems), cardiac rhythm management, and repair and substitution of heart valves. Each year, over one million patients are treated with the devices of Sorin Group in more than 80 countries.
  
For further information, visit: www.sorin.com, or contact:

.pdf